Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD

Exclusion Criteria

• •1. Females who are pregnant, nursing, planning a pregnancy or who are of childbearing potential not using a reliable method of contraception.
• •2. History or current evidence of hypersensitivity to any components of the study medication or fluorescein, as assessed by the investigator.
• •3. Participation in any investigational drug or device study within 30 days prior to baseline
• •4. History or current evidence of a medical condition that may, in the opinion of the investigator, preclude the safe administration of study medication or affect the results of the study.
• •5. Decrease of greater than 150 microns in central subfield thickness as measured by OCT since the last intravitreal injection in the study eye
• •6. Aphakia
• •7. History of pars plana vitrectomy in the study eye
• •8. History of major ophthalmic surgery in the study eye in the past 3 months and any ophthalmic surgery in the study eye within the past 30 days
• •9. History of significant ocular disease or condition other than exudative AMD that may confound results
• •10. Uncontrolled glaucoma (defined as intraocular pressure \>21mm Hg despite treatment with two or more ocular hypotensive medications at baseline)
• •11. No active ocular or periocular infections, or ocular malignancy including lymphoma
• •12. Presence of significant epiretinal membrane
• •13. Significant vitreoretinal traction
• •\-